| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | 746 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen | |
| ALLIANCE PHARMA Aktie jetzt für 0€ handeln | |||||
| 14.05.25 | XFRA DVL: AUSSETZUNG/SUSPENSION | 344 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILALLIANCE PHARMA... ► Artikel lesen | |
| 13.05.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.05.2025 | 789 | Xetra Newsboard | Das Instrument ZRE CH0042615283 DOCMORRIS AG SF 30 EQUITY wird ex Kapitalmassnahme gehandelt am 13.05.2025 The instrument ZRE CH0042615283 DOCMORRIS AG SF 30 EQUITY is traded ex capital adjustment on... ► Artikel lesen | |
| 10.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 299 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| 07.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 323 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 07
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| 06.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 376 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 06
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| 04.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 336 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 04
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| 03.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 353 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 03
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| 28.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 452 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 28
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen | |
| 27.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 242 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 27
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen | |
| 26.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 268 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 26
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen | |
| 25.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 289 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 25
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen | |
| 20.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 335 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 20
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 40,310 | +0,01 % | Abnehmpille schlägt ein: Starker Start ins neue Jahr - Novo Nordisk zeigt Eli Lilly die Rücklichter! | © Foto: Kristian Tuxen Ladegaard Berg - NurPhotoNach einem schwachen Vorjahr meldet sich Novo Nordisk 2026 eindrucksvoll zurück. Die neue Wegovy-Tablette sorgt in den USA für einen starken Marktstart.... ► Artikel lesen | |
| PFIZER | 23,015 | -0,07 % | Opening Bell: Gold/Silber, PepsiCo, Merck & Co, Pfizer, PayPal, Teradyne, Uber/Snap/Alphabet, Nvidia | Die US-Börsen sind zum Wochenstart fester aus dem Handel gegangen. Der Dow Jones gewann 1,05 Prozent, der Nasdaq Composite legte 0,56 Prozent zu. Am Freitag hatte die mögliche Nominierung von Kevin... ► Artikel lesen | |
| SANOFI | 80,49 | +0,05 % | Sanofi und Amgen: Droht diesem Ansatz das Aus? AKTIONÄR-Tipp profitiert! | Viele große Pharma- und Biotech-Firmen sind auf der Suche nach neuen Behandlungsansätzen für die Atopische Dermatitis (Neurodermitis). So auch die großen Branchenvertreter Amgen und Sanofi, die mit... ► Artikel lesen | |
| GSK | 25,300 | +1,12 % | GSK: Besser als erwartet | Der Pharmakonzern konnte ein unerwartet starkes Schlussquartal vorweisen und damit besser abschneiden als gedacht. Der Umsatz von GSK klettert im vergangenen Jahr um 4 % auf knapp 32,7 Mrd. Pfund, währungsbereinigt... ► Artikel lesen | |
| INCYTE | 91,10 | -0,65 % | Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? | ||
| IONIS PHARMACEUTICALS | 71,92 | -1,72 % | Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts | ||
| CSPC PHARMA | 1,031 | +0,49 % | HSI Closes at 26,834, Up 59 pts; HSTI Closes at 5,467, Down 59 pts; CSPC PHARMA Up over 8%; NEW ORIENTAL, HSBC HOLDINGS, MTR CORPORATION, POWER ASSETS, CIMC Hit New Highs; Market Turnover Rises | ||
| ALNYLAM PHARMACEUTICALS | 277,40 | +0,04 % | Alnylam Unveils 'Alnylam 2030' Strategy To Drive Growth And Innovation | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) announced its new five-year strategy, 'Alnylam 2030.' The plan is designed to scale the company's operations by achieving leadership... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,150 | -0,32 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| TRULIEVE CANNABIS | 5,970 | +2,14 % | Trulieve Cannabis Corp.: Trulieve Completes Redemption of All US$368 Million 8.0% Senior Secured Notes due 2026 | TALLAHASSEE, Fla., Dec. 8, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,970 | +0,25 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union | - Company expects to receive a negative opinion following oral explanation feedback and intends to request re-examination upon review of formal adoption.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD)... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,550 | -0,63 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 401,30 | -0,62 % | Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth | ||
| WEST PHARMACEUTICAL SERVICES | 206,70 | -1,85 % | Dividendenbekanntmachungen (28.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ANTERO MIDSTREAM CORPORATION US03676B1026 0,225 USD 0,1868 EUR CAL-MAINE FOODS INC US1280302027 0,719 USD 0,597 EUR CLOROX COMPANY US1890541097 1... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,050 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger | CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company"), today announced that it has commenced an exchange offer (the "Offer") involving... ► Artikel lesen |